Stabilized plasmid-lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection - PubMed (original) (raw)
Stabilized plasmid-lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection
M A Monck et al. J Drug Target. 2000.
Abstract
A previous study has shown that plasmid DNA can be encapsulated in lipid particles (SPLP, "stabilized plasmid lipid particles") of approximately 70 nm diameter composed of 1,2-dioleoyl-3-phosphatidyl-ethanolamine (DOPE), the cationic lipid N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC) and poly(ethylene glycol) conjugated to ceramide (PEG-Cer) using a detergent dialysis process (Wheeler et al. (1999) Gene Therapy 6, 271-281). In this work we evaluated the potential of these SPLPs as systemic gene therapy vectors, determining their pharmacokinetics and the biodistribution of the plasmid and lipid components. It is shown that the blood clearance and the biodistribution of the SPLPs can be modulated by varying the acyl chain length of the ceramide group used as lipid anchor for the PEG polymer. Circulation lifetimes observed for SPLPs with PEG-CerC14 and PEG-CerC20 were t(1/2) = approximately 1 and approximately 10 h, respectively. The SPLPs are stable while circulating in the blood and the encapsulated DNA is fully protected from degradation by serum nucleases. The accelerated clearance of SPLPs with PEG-CerC14 is accompanied by increased accumulation in liver and spleen as compared to PEG-CerC20 SPLPs. Delivery of intact plasmid to liver and spleen was detected. Significant accumulation (approximately 10% of injected dose) of the long circulating SPLPs with PEG-CerC20 in a distal tumor (Lewis lung tumor in the mouse flank) was observed following i.v. application and delivery of intact plasmid to tumor tissue at approximately 6% injected dose/g tissue is demonstrated.
Similar articles
- Encapsulation of plasmid DNA in stabilized plasmid-lipid particles composed of different cationic lipid concentration for optimal transfection activity.
Saravolac EG, Ludkovski O, Skirrow R, Ossanlou M, Zhang YP, Giesbrecht C, Thompson J, Thomas S, Stark H, Cullis PR, Scherrer P. Saravolac EG, et al. J Drug Target. 2000;7(6):423-37. doi: 10.3109/10611860009102217. J Drug Target. 2000. PMID: 10758913 - Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties.
Zhang YP, Sekirov L, Saravolac EG, Wheeler JJ, Tardi P, Clow K, Leng E, Sun R, Cullis PR, Scherrer P. Zhang YP, et al. Gene Ther. 1999 Aug;6(8):1438-47. doi: 10.1038/sj.gt.3300965. Gene Ther. 1999. PMID: 10467368 - Stabilized plasmid-lipid particles: construction and characterization.
Wheeler JJ, Palmer L, Ossanlou M, MacLachlan I, Graham RW, Zhang YP, Hope MJ, Scherrer P, Cullis PR. Wheeler JJ, et al. Gene Ther. 1999 Feb;6(2):271-81. doi: 10.1038/sj.gt.3300821. Gene Ther. 1999. PMID: 10435112 - "Diffusible-PEG-lipid stabilized plasmid lipid particles".
MacLachlan I, Cullis P. MacLachlan I, et al. Adv Genet. 2005;53:157-88. Adv Genet. 2005. PMID: 16240993 Review. - Long-circulating vectors for the systemic delivery of genes.
Fenske DB, MacLachlan I, Cullis PR. Fenske DB, et al. Curr Opin Mol Ther. 2001 Apr;3(2):153-8. Curr Opin Mol Ther. 2001. PMID: 11338928 Review.
Cited by
- The effect of cholesterol domains on PEGylated liposomal gene delivery in vitro.
Xu L, Wempe MF, Anchordoquy TJ. Xu L, et al. Ther Deliv. 2011 Apr;2(4):451-60. doi: 10.4155/tde.11.13. Ther Deliv. 2011. PMID: 22428082 Free PMC article. - Lipid-based nanoparticles for nucleic acid delivery.
Li W, Szoka FC Jr. Li W, et al. Pharm Res. 2007 Mar;24(3):438-49. doi: 10.1007/s11095-006-9180-5. Pharm Res. 2007. PMID: 17252188 Review. - Effect of cholesterol nanodomains on the targeting of lipid-based gene delivery in cultured cells.
Xu L, Anchordoquy TJ. Xu L, et al. Mol Pharm. 2010 Aug 2;7(4):1311-7. doi: 10.1021/mp100097b. Mol Pharm. 2010. PMID: 20568694 Free PMC article. - Nanovehicular intracellular delivery systems.
Prokop A, Davidson JM. Prokop A, et al. J Pharm Sci. 2008 Sep;97(9):3518-90. doi: 10.1002/jps.21270. J Pharm Sci. 2008. PMID: 18200527 Free PMC article. Review. - Understanding In Vivo Fate of Nucleic Acid and Gene Medicines for the Rational Design of Drugs.
Fumoto S, Yamamoto T, Okami K, Maemura Y, Terada C, Yamayoshi A, Nishida K. Fumoto S, et al. Pharmaceutics. 2021 Jan 26;13(2):159. doi: 10.3390/pharmaceutics13020159. Pharmaceutics. 2021. PMID: 33530309 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical